Biovica International
2.46 SEK -0.61%Be the first to follow this company
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Revenue
590K
EBIT %
-6,306.78 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
BIOVIC B
Daily low / high price
2.355 / 2.635
SEK
Market cap
206.78M SEK
Turnover
31.3K SEK
Volume
13K
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Anders Rylander Investment AB | 10.7 % | 16.9 % |
Avanza Pension | 7.1 % | 6.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Biovica receives positive patent notification for immunotherapies
Redeye: Biovica - Commercial progress despite a quarter with modest sales
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools